Shares of Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $5.71, but opened at $5.35. Valneva shares last traded at $5.3950, with a volume of 176 shares.
Analyst Upgrades and Downgrades
VALN has been the topic of a number of recent analyst reports. TD Cowen started coverage on shares of Valneva in a research report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $9.30.
Check Out Our Latest Stock Analysis on Valneva
Valneva Stock Down 2.5%
The firm has a market capitalization of $504.44 million, a price-to-earnings ratio of -2.53 and a beta of 1.37. The stock has a 50 day moving average of $6.18 and a 200 day moving average of $6.87. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04.
Valneva (NASDAQ:VALN – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. As a group, analysts expect that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current fiscal year.
Valneva Company Profile
Valneva SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.
Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea.
Featured Stories
- Five stocks we like better than Valneva
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
- 3 Waste Services Stocks With More Growth Than You Might Expect
- Alphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026
- 3 Tech Stocks Boosting Buyback Capacity in the Face of the Sector’s Recent Tumble
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
